Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Theron, A J ^a,b   Steel, H C ^a   Tintinger, G R ^a   Gravett, C M ^a   Anderson, R ^a   Feldman, C ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; CETIRIZINE; CYCLIC AMP PHOSPHODIESTERASE; CYSTEINYL LEUKOTRIENE RECEPTOR 1; CYSTEINYL LEUKOTRIENE RECEPTOR 1 ANTAGONIST; DESLORATADINE; ELASTASE; FLUTICASONE PROPIONATE; FORMOTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IPRATROPIUM BROMIDE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; MONTELUKAST; PEPTIDOLEUKOTRIENE; PRANLUKAST; PROSTAGLANDIN SYNTHASE; PURINERGIC P2Y RECEPTOR; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; UNCLASSIFIED DRUG; ZAFIRLUKAST; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; CHROMONE DERIVATIVE; CYCLIC GMP PHOSPHODIESTERASE; IMMUNOLOGIC FACTOR; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE RECEPTOR; QUINOLINE DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE;

ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; ATHEROSCLEROSIS; CELL ACTIVITY; CELL FUNCTION; CHILDHOOD DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOSOL; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; EOSINOPHILIC GASTROENTERITIS; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; GERIATRIC DISORDER; HAY FEVER; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; MONOTHERAPY; MYELOID DENDRITIC CELL; NEUTROPHIL; PERENNIAL RHINITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SMOKING; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC DISEASE; SYSTEMIC MASTOCYTOSIS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY;

3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ACETATES; ANTI-ASTHMATIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; ASTHMA; CHROMONES; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LEUKOTRIENE ANTAGONISTS; MONOCYTES; NEUTROPHILS; NF-KAPPA B; QUINOLINES; RECEPTORS, LEUKOTRIENE; TOSYL COMPOUNDS;

EID: 84902137136     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/608930     Document Type: Review

References (175)

1. Peters-Golden M., Henderson W. R. Jr., Mechanisms of disease: leukotrienes. The New England Journal of Medicine 2007 357 18 1798 1854 2-s2.0-35748961720 10.1056/NEJMra071371 (Pubitemid 350044805)
2. Okunishi K., Peters-Golden M., Leukotrienes and airway inflammation. Biochimica et Biophysica Acta 2011 1810 11 1096 1102 2-s2.0-80054923010 10.1016/j.bbagen.2011.02.005
3. Scott J. P., Peters-Golden M., Antileukotriene agents for the treatment of lung disease. American Journal of Respiratory and Critical Care Medicine 2013 188 5 538 544
4. Amlani S., Nadarajah T., McIvor R. A., Montelukast for the treatment of asthma in the adult population. Expert Opinion on Pharmacotherapy 2011 12 13 2119 2128 2-s2.0-80051491390 10.1517/14656566.2011.600689
5. Pacheco Y., Freymond N., Devouassoux G., Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities. Journal of Asthma 2014 51 1 1 17
6. Kim D. C., Hsu F. I., Barrett N. A., Friend D. S., Grenningloh R., Ho I.-C., Al-Garawi A., Lora J. M., Lam B. K., Austen K. F., Kanaoka Y., Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. The Journal of Immunology 2006 176 7 4440 4448 2-s2.0-33646036422 (Pubitemid 44264424)
7. Jiang Y., Kanaoka Y., Feng C., Nocka K., Rao S., Boyce J. A., Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. The Journal of Immunology 2006 177 5 2755 2759 2-s2.0-33747790575 (Pubitemid 44277788)
8. Kondeti V., Duah E., Al-Azzam N., Thodeti C. K., Boyce J. A., Paruchuri S., Differential regulation of cysteinyl leukotriene receptor signaling by protein kinase C in human mast cells. PLoS ONE 2013 8 8 e71536
9. Serezani C. H. C., Aronoff D. M., Jancar S., Mancuso P., Peters-Golden M., Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase. Blood 2005 106 3 1067 1075 2-s2.0-23044502301 10.1182/blood-2004-08-3323 (Pubitemid 41076456)
10. Ichiyama T., Kajimoto M., Hasegawa M., Hashimoto K., Matsubara T., Furukawa S., Cysteinyl leukotrienes enhance tumour necrosis factor- induced matrix metalloproteinase-9 in human monocytes/macrophages. Clinical & Experimental Allergy 2007 37 4 608 614 2-s2.0-34047231902 10.1111/j.1365-2222. 2007.02692.x (Pubitemid 46537750)
11. Woszczek G., Chen L.-Y., Nagineni S., Kern S., Barb J., Munson P. J., Logun C., Danner R. L., Shelhamer J. H., Leukotriene D4 induces gene expression in human monocytes through cysteinyl leukotriene type I receptor. Journal of Allergy & Clinical Immunology 2008 121 1 215 221 2-s2.0-38149000696 10.1016/j.jaci.2007.09.013
12. Hashimoto K., Ichiyama T., Hasegawa M., Hasegawa S., Matsubara T., Furukawa S., Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor- b pathways. International Archives of Allergy and Immunology 2009 149 3 275 282 2-s2.0-59849121110 10.1159/000199724
13. Ichiyama T., Hasegawa M., Hashimoto K., Matsushige T., Hirano R., Furukawa S., Cysteinyl leukotrienes induce macrophage inflammatory protein-1 in human monocytes/macrophages. International Archives of Allergy and Immunology 2009 148 2 147 153 2-s2.0-51849091383 10.1159/000155745
14. Thompson C., Cloutier A., Bossé Y., Thivierge M., Le Gouill C., Larivée P., McDonald P. P., Stankova J., Rola-Pleszczynski M., CysLT1 receptor engagement induces activator protein-1- and NF- B-dependent IL-8 expression. American Journal of Respiratory Cell and Molecular Biology 2006 35 6 697 704 2-s2.0-33845428771 10.1165/rcmb.2005-0407OC (Pubitemid 44901859)
15. Poulin S., Thompson C., Thivierge M., Véronneau S., McMahon S., Dubois C. M., Stankova J., Rola-Pleszczynski M., Cysteinyl-leukotrienes induce vascular endothelial growth factor production in human monocytes and bronchial smooth muscle cells. Clinical & Experimental Allergy 2011 41 2 204 217 2-s2.0-78651443369 10.1111/j.1365-2222.2010.03653.x
16. Haneda Y., Hasegawa S., Hirano R., Hashimoto K., Ohsaki A., Ichiyama T., Leukotriene D4 enhances tumor necrosis factor- induced vascular endothelial growth factor production in human monocytes/macrophages. Cytokine 2011 55 1 24 28 2-s2.0-79956365071 10.1016/j.cyto.2011.03.018
17. Fregonese L., Silvestri M., Sabatini F., Rossi G. A., Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clinical & Experimental Allergy 2002 32 5 745 750 2-s2.0-0035999859 10.1046/j.1365-2222.2002.01384.x (Pubitemid 34534022)
18. Meliton A. Y., Munoz N. M., Leff A. R., Blockade of avidity and focal clustering of β 2-integrin by cysteinyl leukotriene antagonism attenuates eosinophil adhesion. Journal of Allergy & Clinical Immunology 2007 120 6 1316 1323 2-s2.0-36849047839 10.1016/j.jaci.2007.07.038 (Pubitemid 350225682)
19. Mori M., Takaku Y., Kobayashi T., Hagiwara K., Kanazawa M., Nagata M., Eosinophil superoxide anion generation induced by adhesion molecules and leukotriene D4. International Archives of Allergy and Immunology 2009 149 1 31 38 2-s2.0-67650270662 10.1159/000210651
20. Neves J. S., Radke A. L., Weller P. F., Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. Journal of Allergy & Clinical Immunology 2010 125 2 477 482 2-s2.0-75849155173 10.1016/j.jaci.2009.11.029
21. Itagaki K., Barton B. E., Murphy T. F., Taheri S., Shu P., Huang H., Jordan M. L., Eicosanoid-induced store-operated calcium entry in dendritic cells. Journal of Surgical Research 2011 169 2 301 310 2-s2.0-79960265376 10.1016/j.jss.2009.10.016
22. Machida I., Matsuse H., Kondo Y., Kawano T., Saeki S., Tomari S., Obase Y., Fukushima C., Kohno S., Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma. The Journal of Immunology 2004 172 3 1833 1838 2-s2.0-1642443955 (Pubitemid 38116832)
23. Heimbürger M., Palmblad J. E., Effects of leukotriene C4 and D4, histamine and bradykinin on cytosolic calcium concentrations and adhesiveness of endothelial cells and neutrophils. Clinical & Experimental Immunology 1996 103 3 454 460
24. Lärfars G., Lantoine F., Devynck M.-A., Palmblad J., Gyllenhammar H., Activation of nitric oxide release and oxidative metabolism by leukotrienes B4, C4, and D4 in human polymorphonuclear leukocytes. Blood 1999 93 4 1399 1405 2-s2.0-0344076063 (Pubitemid 29076156)
25. Theron A. J., Gravett C. M., Steel H. C., Tintinger G. R., Feldman C., Anderson R., Leukotrienes C4 and D4 sensitize human neutrophils for hyperreactivity to chemoattractants. Inflammation Research 2009 58 5 263 268 2-s2.0-67349132463 10.1007/s00011-008-8049-y
26. Anderson R., Theron A. J., Gravett C. M., Steel H. C., Tintinger G. R., Feldman C., Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. British Journal of Pharmacology 2009 156 1 105 115 2-s2.0-65549132863 10.1111/j.1476-5381.2008.00012.x
27. Cheng H., Leff J. A., Amin R., Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharmaceutical Research 1996 13 3 445 448 (Pubitemid 26114730)
28. Knorr B., Nguyen H. H., Kearns G. L., Villaran C., Boza M. L., Reiss T. F., Rogers J. D., Zhang J., Larson P., Spielberg S., Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. The Journal of Clinical Pharmacology 2001 41 6 612 619 2-s2.0-17844373539 10.1177/00912700122010492 (Pubitemid 32493355)
29. Tintinger G. R., Feldman C., Theron A. J., Anderson R., Montelukast: more than a cysteinyl leukotriene receptor antagonist? TheScientificWorldJournal 2010 10 2403 2413 2-s2.0-78650277518 10.1100/tsw.2010.229
30. Ramires R., Caiaffa M. F., Tursi A., Haeggström J. Z., Macchia L., Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochemical and Biophysical Research Communications 2004 324 2 815 821 2-s2.0-5144232253 10.1016/j.bbrc.2004.09.125 (Pubitemid 39345588)
31. Woszczek G., Chen L.-Y., Alsaaty S., Nagineni S., Shelhamer J. H., Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists. The Journal of Immunology 2010 184 4 2219 2225 2-s2.0-77949905796 10.4049/jimmunol.0900071
32. Fogli S., Stefanelli F., Martelli A., Protective effect of high-dose montelukast on salbutamol-induced homologous desensitisation in airway smooth muscle. Pulmonary Pharmacology & Therapeutics 2013 26 6 693 699 10.1016/j.pupt.2013.06.006
33. Serezani C. H., Ballinger M. N., Aronoff D. M., Peters-Golden M., Cyclic AMP: master regulator of innate immune cell function. American Journal of Respiratory Cell and Molecular Biology 2008 39 2 127 132 2-s2.0-48649087006 10.1165/rcmb.2008-0091TR
34. Fogli S., Stefanelli F., Neri T., Montelukast prevents microparticle-induced inflammatory and functional alterations in human bronchial smooth muscle cells. Pharmacological Research 2013 76 149 156
35. Tahan F., Jazrawi E., Moodley T., Rovati G. E., Adcock I. M., Montelukast inhibits tumour necrosis factor- mediated interleukin-8 expression through inhibition of nuclear factor- B p65-associated histone acetyltransferase activity. Clinical & Experimental Allergy 2008 38 5 805 811 2-s2.0-42249106829 10.1111/j.1365-2222.2008.02963.x (Pubitemid 351550673)
36. Parry G. C., Mackman N., Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NFkappaB-mediated transcription. The Journal of Immunology 1997 159 11 5450 5456 (Pubitemid 127470072)
37. Kahnt A. S., Rörsch R., Diehl O., Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity. Biochemical Pharmacology 2013 86 2 286 296
38. Robinson A. J., Kashanin D., O'Dowd F., Williams V., Walsh G. M., Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of cysLT1R antagonism. Journal of Leukocyte Biology 2008 83 6 1522 1529 2-s2.0-45949101942 10.1189/jlb.1007717 (Pubitemid 351960334)
39. Langlois A., Ferland C., Tremblay G. M., Laviolette M., Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. Journal of Allergy & Clinical Immunology 2006 118 1 113 119 2-s2.0-33745664801 10.1016/j.jaci.2006.03.010 (Pubitemid 43964855)
40. Gravett C. M., Theron A. J., Steel H. C., Tintinger G. R., Cockeran R., Feldman R., Anderson C., Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils. European Respiratory Journal 2010 36 6 1417 1424 2-s2.0-78649756979 10.1183/09031936.00157409
41. Flamand N., Surette M. E., Picard S., Bourgoin S., Borgeat P., Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Molecular Pharmacology 2002 62 2 250 256 2-s2.0-0036076153 10.1124/mol.62.2.250 (Pubitemid 34804103)
42. Savari S., Liu M., Zhang Y., Sime W., Sjölander A., CysLT1R antagonists inhibit tumor growth in a xenograft model of colon cancer. PLoS ONE 2013 8 9 e73466
43. Pathomthongtaweechai N., Soodvilai S., Chatsudthipong V., Muanprasat C., Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase. European Journal of Pharmacology 2014 724 67 76
44. Cacicedo J. M., Yagihashi N., Keaney J. F. Jr., Ruderman N. B., Ido Y., AMPK inhibits fatty acid-induced increases in NF- B transactivation in cultured human umbilical vein endothelial cells. Biochemical and Biophysical Research Communications 2004 324 4 1204 1209 2-s2.0-14344257169 10.1016/j.bbrc.2004.09. 177 (Pubitemid 40292150)
45. Tintinger G. R., Steel H. C., Anderson R., Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control. Clinical & Experimental Immunology 2005 141 2 191 200 2-s2.0-22344443770 10.1111/j.1365-2249.2005.02800.x (Pubitemid 41003342)
46. Tintinger G. R., Steel H. C., Theron A. J., Anderson R., Pharmacological control of neutrophil-mediated inflammation: strategies targeting calcium handling by activated polymorphonuclear leukocytes. Drug Design, Development and Therapy 2008 2 95 104 2-s2.0-77953680768
47. Holmsen H., Storm E., Day H. J., Determination of ATP and ADP in blood platelets: a modification of the firefly luciferase assay for plasma. Analytical Biochemistry 1972 46 2 489 501 2-s2.0-0015323497
48. Nayak A., A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opinion on Pharmacotherapy 2004 5 3 679 686 2-s2.0-1542609873 10.1517/14656566.5.3.679 (Pubitemid 38344321)
49. Riccioni G., Bucciarelli T., Mancini B., di Ilio C., D'Orazio N., Antileukotriene drugs: clinical application, effectiveness and safety. Current Medicinal Chemistry 2007 14 18 1966 1977 2-s2.0-34547657273 10.2174/ 092986707781368522 (Pubitemid 47209107)
50. Scow D. T., Luttermoser G. K., Dickerson K. S., Leukotriene inhibitors in the treatment of allergy and asthma. American Family Physician 2007 75 1 65 70 2-s2.0-33846098277 (Pubitemid 46064484)
51. Grainger J., Drake-Lee A., Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clinical Otolaryngology 2006 31 5 360 367 2-s2.0-33749452692 10.1111/j.1749-4486.2006.01276.x (Pubitemid 44511155)
52. Nayak A., Langdon R. B., Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007 67 6 887 901 2-s2.0-34247257959 (Pubitemid 46607389)
53. Sardana N., Santos C., Lehman E., Craig T., A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the rhinitis severity score. Allergy and Asthma Proceedings 2010 31 1 5 9 2-s2.0-76149111141 10.2500/aap.2010.31.3308
54. Ciebiada M., Gorska-Ciebiada M., Barylski M., Kmiecik T., Gorski P., Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. American Journal of Rhinology and Allergy 2011 25 1 e1 e6 2-s2.0-79551529499 10.2500/ajra.2011.25.3540
55. Okubo K., Baba K., A double-blind non-inferiority clinical study of montelukast, a cysteinyl leukotriene receptor 1 antagonist, compared with pranlukast in patients with seasonal allergic rhinitis. Allergology International 2008 57 4 383 390 2-s2.0-59549105114 10.2332/allergolint.O-08-533
56. Wenzel S. E., The role of leukotrienes in asthma. Prostaglandins Leukotrienes and Essential Fatty Acids 2003 69 2-3 145 155 2-s2.0-0041573180 10.1016/S0952-3278(03)00075-9 (Pubitemid 36980619)
57. Kavuru M. S., Subramony R., Vann A. R., Antileukotrienes and asthma: alternative or adjunct to inhaled steroids? Cleveland Clinic Journal of Medicine 1998 65 10 519 526 2-s2.0-0032448252 (Pubitemid 29072262)
58. García-Marcos L., Schuster A., Pérez-Yarza E. G., Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Safety 2003 26 7 483 518 2-s2.0-0037564370 10.2165/00002018-200326070-00004 (Pubitemid 36629786)
59. Peters S. P., Leukotriene receptor antagonists in asthma therapy. Journal of Allergy & Clinical Immunology 2003 111 1 S62 S70 2-s2.0-0037252473 10.1067/mai.2003.21 (Pubitemid 36135512)
60. Polosa R., Critical appraisal of antileukotriene use in asthma management. Current Opinion in Pulmonary Medicine 2007 13 1 24 30 2-s2.0-33845421478 10.1097/MCP.0b013e3280107bda (Pubitemid 44900709)
61. O'Byrne P. M., Gauvreau G. M., Murphy D. M., Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma. Journal of Allergy & Clinical Immunology 2009 124 3 397 403 2-s2.0-69349096059 10.1016/j.jaci.2009.05.029
62. Montuschi P., Peters-Golden M. L., Leukotriene modifiers for asthma treatment. Clinical & Experimental Allergy 2010 40 12 1732 1741 2-s2.0-78349274904 10.1111/j.1365-2222.2010.03630.x
63. Montuschi P., Role of leukotrienes and leukotriene modifiers in asthma. Pharmaceuticals 2010 3 6 1792 1811 2-s2.0-77954896449 10.3390/ph3061792
64. Blake K. V., Montelukast: data from clinical trials in the management of asthma. Annals of Pharmacotherapy 1999 33 12 1299 1314 2-s2.0-0033401342 (Pubitemid 30022809)
65. Jarvis B., Markham A., Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 2000 59 4 891 928 2-s2.0-0034010246 (Pubitemid 30232328)
66. Paggiaro P., Bacci E., Montelukast in asthma: a review of its efficacy and place in therapy. Therapeutic Advances in Chronic Disease 2011 2 1 47 58 2-s2.0-79960066863 10.1177/2040622310383343
67. Tsai J.-J., Chan S.-C., Ho C.-K., Su Y.-C., Feng T.-C., Efficacy of zafirlukast in the treatment of patients with bronchial asthma. Journal of Microbiology, Immunology and Infection 2001 34 1 63 70 2-s2.0-0035050082 (Pubitemid 32299240)
68. Dunn C. J., Goa K. L., Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs 2001 61 2 285 315 2-s2.0-0035105775 (Pubitemid 32215290)
69. Riccioni G., Castronuovo M., de Benedictis M., Pace-Palitti V., di Gioacchino M., Della Vecchia R., Schiavone C., Sensi S., Guagnano M. T., Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma. International Journal of Immunopathology and Pharmacology 2001 14 2 87 92 2-s2.0-0034880282 (Pubitemid 32744447)
70. Huang C.-J., Wang C.-H., Liu W.-T., Yang M.-C., Lin H.-C., Yu C.-T., Shiao C.-J., Tan C.-C., Yang C.-K., Kuo H. P., Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study. Chang Gung Medical Journal 2003 26 8 554 560 2-s2.0-0142152629 (Pubitemid 37314539)
71. Silverman R. A., Nowak R. M., Korenblat P. E., Skobeloff E., Chen Y., Bonuccelli C. M., Miller C. J., Simonson S. G., Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest 2004 126 5 1480 1489 2-s2.0-8744310125 10.1378/chest.126.5.1480 (Pubitemid 39525020)
72. Tomari S., Shimoda T., Kawano T., Mitsuta K., Obase Y., Fukushima C., Matsuse H., Kohno S., Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Annals of Allergy, Asthma & Immunology 2001 87 2 156 161 2-s2.0-0034857142 (Pubitemid 32783125)
73. Keam S. J., Lyseng-Williamson K. A., Goa K. L., Korenblat P. E., Lockey R. F., Obase Y., Rovati G. E., Sampson A. P., Smith L. J., Tamura G., Pranlukast: a review of its use in the management of asthma. Drugs 2003 63 10 991 1019 2-s2.0-0038367655 10.2165/00003495-200363100-00005 (Pubitemid 36570535)
74. Niitsuma T., Izawa J., Maruoka N., Nukaga M., Tsuji A., Okita M., Sakurai K., Morita S., Tsuyuguchi M., Matsumura Y., Hayashi T., Clinical evaluation of response to long-term treatment with Pranlukast in patients with bronchial asthma. Journal of Investigational Allergology and Clinical Immunology 2004 14 4 284 291 2-s2.0-20144364351 (Pubitemid 40378861)
75. Yanagawa H., Sugita A., Azuma M., Ogawa H., Kitamuro C., Yoneda K., Shinkawa K., Tani K., Sone S., Long-term follow-up of pulmonary function in bronchial asthma patients treated with pranlukast. Lung 2004 182 1 51 58 2-s2.0-1142273101 10.1007/s00408-003-1044-8 (Pubitemid 38210599)
76. Horiguchi T., Tachikawa S., Kondo R., Miyazaki J., Shiga M., Hirose M., Kobayashi K., Hayashi N., Ohira D., Nasu T., Otake Y., Hata H., Comparative evaluation of the leukotriene receptor antagonist pranlukast versus the steroid inhalant fluticasone in the therapy of aged patients with mild bronchial asthma. Arzneimittel-Forschung 2007 57 2 87 91 2-s2.0-33847747446 (Pubitemid 46383948)
77. Ohbayashi H., Shibata N., Hirose T., Adachi M., Additional effects of pranlukast in salmeterol/fluticasone combination therapy for the asthmatic distal airway in a randomized crossover study. Pulmonary Pharmacology & Therapeutics 2009 22 6 574 579 2-s2.0-71249131928 10.1016/j.pupt.2009.08.002
78. Yasui H., Fujisawa T., Inui N., Kato M., Hashimoto D., Enomoto N., Nakamura Y., Shirai T., Suda T., Nakamura H., Chida K., Impact of add-on pranlukast in stable asthma; the additive effect on peripheral airway inflammation. Respiratory Medicine 2012 106 4 508 514 2-s2.0-84857918547 10.1016/j.rmed.2011.12.014
79. Vignola A. M., Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting β 2-agonists on asthma pathophysiology: a review of the evidence. Drugs 2003 63 2 35 51 2-s2.0-0242552281 10.2165/00003495-200363002-00004 (Pubitemid 37421787)
80. Price D., Musgrave S. D., Shepstone L., Hillyer E. V., Sims E. J., Gilbert R. F. T., Juniper E. F., Ayres J. G., Kemp L., Blyth A., Wilson E. C. F., Wolfe S., Freeman D., Mugford H. M., Murdoch J., Harvey I., Leukotriene antagonists as first-line or add-on asthma-controller therapy. The New England Journal of Medicine 2011 364 18 1695 1707 2-s2.0-79955716906 10.1056/NEJMoa1010846
81. Creticos P. S., Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists. Drugs 2003 63 2 1 20 2-s2.0-0242575321 (Pubitemid 37421785)
82. Chauhan B. F., Ducharme F. M., Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2012 5 CD002314 2-s2.0-84864507034
83. Ducharme F. M., Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. British Medical Journal 2002 324 7353 1545 1548 2-s2.0-0037193820 (Pubitemid 34713129)
84. Ram F. S., Cates C. J., Ducharme F. M., Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database of Systematic Reviews 2005 4 1 CD003137 2-s2.0-18944364933
85. Joos S., Miksch A., Szecsenyi J., Wieseler B., Grouven U., Kaiser T., Schneider A., Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008 63 5 453 462 2-s2.0-43949129790 10.1136/thx.2007.081596 (Pubitemid 351698876)
86. Lipworth B. J., Jackson C. M., Second-line controller therapy for persistent asthma uncontrolled on inhaled corticosteroids. Drugs 2002 62 16 2315 2332 2-s2.0-0036428216 (Pubitemid 35316383)
87. Helms P. J., Corticosteroid-sparing options in the treatment of childhood asthma. Drugs 2000 59 1 15 22 2-s2.0-0034070121 (Pubitemid 30179164)
88. Bisgaard H., Leukotriene modifiers in pediatric asthma management. Pediatrics 2001 107 2 381 390 2-s2.0-0035145039 10.1542/peds.107.2.381 (Pubitemid 32121256)
89. Knorr B., Franchi L. M., Bisgaard H., Vermeulen J. H., LeSouef P., Santanello N., Michele T. M., Reiss T. F., Nguyen H. H., Bratton D. L., Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001 108 3 E48 2-s2.0-0035461065
90. Spahr J. E., Krawiec M., Leukotriene receptor antagonists-risks and benefits for use in paediatric asthma. Expert Opinion on Drug Safety 2004 3 3 173 185 2-s2.0-2942689443 10.1517/eods.3.3.173.31075 (Pubitemid 38765200)
91. Wahn U., Dass S. B., Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clinical Therapeutics 2008 30 1 1026 1035 2-s2.0-47249151764 10.1016/j.clinthera.2008.05.018 (Pubitemid 351982027)
92. del Giudice M. M., Pezzulo A., Capristo C., Alterio E., Caggiano S., de Benedictis D., Capristo A. F., Leukotriene modifiers in the treatment of asthma in children. Therapeutic Advances in Respiratory Disease 2009 3 5 245 251 2-s2.0-70449841239 10.1177/1753465809348014
93. Gravett C. M., Tintinger G. R., Theron A. J., Anderson R., Feldman C., Green R., Montelukast sodium: administration to children to control intermittent asthma. Clinical Medicine Reviews in Therapeutics 2010 2 1 1 10
94. Amlani S., McIvor R. A., Montelukast in childhood asthma: what is the evidence for its use? Expert Review of Respiratory Medicine 2011 5 1 17 25 2-s2.0-79952149705 10.1586/ers.10.90
95. Dumitru C., Chan S. M. H., Turcanu V., Role of leukotriene receptor antagonists in the management of pediatric asthma. Pediatric Drugs 2012 14 5 317 330 2-s2.0-84865366781 10.2165/11599930-000000000-00000
96. Massingham K., Fox S., Smaldone A., Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids. Journal of Pediatric Health Care 2014 28 1 51 62 2-s2.0-84872091766 10.1016/j.pedhc.2012.11.005
97. Bozek A., Warkocka-Szoltysek B., Filipowska-Gronska A., Jarzab J., Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. Journal of Asthma 2012 49 5 530 534 2-s2.0-84862862358 10.3109/02770903.2012.680638
98. Scichilone N., Battaglia S., Benfante A., Bellia V., Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients. Clinical Interventions in Aging 2013 8 1329 1337
99. Meltzer E. O., Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of 'one linked airway disease'. Annals of Allergy, Asthma & Immunology 2000 84 2 176 187 2-s2.0-0034102104 (Pubitemid 30141598)
100. Virchow J. C., Bachert C., Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respiratory Medicine 2006 100 11 1952 1959 2-s2.0-33749044069 10.1016/j.rmed.2006.02.026 (Pubitemid 44490289)
101. Valovirta E., Managing co-morbid asthma with allergic rhinitis: targeting the one-airway with leukotriene receptor antagonists. World Allergy Organization Journal 2012 5 3 S210 S211 2-s2.0-84863738611 10.1097/WOX. 0b013e31821d1186
102. Piatti G., Ceriotti L., Cavallaro G., Ambrosetti U., Mantovani M., Pistone A., Centanni S., Effects of zafirlukast on bronchial asthma and allergic rhinitis. Pharmacological Research 2003 47 6 541 547 2-s2.0-0038639212 10.1016/S1043-6618(03)00017-3 (Pubitemid 36542934)
103. Camargo C. A. Jr., Gurner D. M., Smithline H. A., Chapela R., Fabbri L. M., Green S. A., Malice M.-P., Legrand C., Dass S. B., Knorr B. A., Reiss T. F., A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. Journal of Allergy & Clinical Immunology 2010 125 2 374 380 2-s2.0-75849157844 10.1016/j.jaci.2009.11.015
104. Hallstrand T. S., Henderson W. R. Jr., The evolving role of intravenous leukotriene modifiers in acute asthma. Journal of Allergy & Clinical Immunology 2010 125 2 381 382 2-s2.0-75849139980 10.1016/j.jaci.2009.12.991
105. Adachi M., Taniguchi H., Tohda Y., Sano Y., Ishine T., Smugar S. S., Hisada S., The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in japanese patients. Journal of Asthma 2012 49 6 649 656 2-s2.0-84863893566 10.3109/02770903.2012.690479
106. Morris C. R., Becker A. B., Piñeiro A., Massaad R., Green S. A., Smugar S. S., Gurner D. M., A randomized, placebo-controlled study of intravenous montelukast in children with acute asthma. Annals of Allergy, Asthma & Immunology 2010 104 2 161 171 2-s2.0-76649089020 10.1016/j.anai.2009.11. 065
107. Ramsay C. F., Pearson D., Mildenhall S., Wilson A. M., Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Thorax 2011 66 1 7 11 2-s2.0-78650185854 10.1136/thx.2010.135038
108. Zubairi A. B. S., Salahuddin N., Khawaja A., Awan S., Shah A. A., Haque A. S., Husain S. J., Rao N., Khan J. A., A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation. BMC Pulmonary Medicine 2013 13 1, article 20 2-s2.0-84875306673 10.1186/1471-2466- 13-20
109. Todi V. K., Lodha R., Kabra S. K., Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial. Archives of Disease in Childhood 2010 95 7 540 543 2-s2.0-77953787641 10.1136/adc.2009.168567
110. Capsomidis A., Tighe M., Is oral montelukast beneficial in treating acute asthma exacerbations in children? Archives of Disease in Childhood 2010 95 11 948 950 2-s2.0-78349250133 10.1136/adc.2010.200048
111. Jolobe O. M. P., Oral montelukast may have a role in severe and in life-threatening acute asthma. Archives of Disease in Childhood 2011 96 3 322 2-s2.0-79951678610 10.1136/adc.2010.205989
112. Watts K., Chavasse R. J. P. G., Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews 2012 5 CD006100 2-s2.0-84864519124
113. Price D., Popov T. A., Bjermer L., Lu S., Petrovic R., Vandormael K., Mehta A., Strus J. D., Polos P. G., Philip G., Effect of montelukast for treatment of asthma in cigarette smokers. Journal of Allergy & Clinical Immunology 2013 131 3 763 771 2-s2.0-84875220579 10.1016/j.jaci.2012.12.673
114. Braganza G., Chaudhuri R., Thomson N. C., Treating patients with respiratory disease who smoke. Therapeutic Advances in Respiratory Disease 2008 2 2 95 107 2-s2.0-58149242033 10.1177/1753465808089697 (Pubitemid 351472134)
115. Kemp J. P., Dockhorn R. J., Shapiro G. G., Nguyen H. H., Reiss T. E., Seidenberg B. C., Knorr B., Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. Journal of Pediatrics 1998 133 3 424 428 2-s2.0-0031660267 10.1016/S0022-3476(98)70281-1 (Pubitemid 28413629)
116. Busse W. W., McGill K. A., Horwitz R. J., Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Clinical & Experimental Allergy 1999 29 2 110 115 2-s2.0-0033011604 (Pubitemid 29314673)
117. Mastalerz L., Gawlewicz-Mroczka A., Nizankowska E., Cmiel A., Szczeklik A., Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clinical & Experimental Allergy 2002 32 9 1360 1365 2-s2.0-0036037468 10.1046/j.1365-2745. 2002.01484.x (Pubitemid 35024964)
118. Tan R. A., Spector S. L., Exercise-induced asthma: diagnosis and management. Annals of Allergy, Asthma & Immunology 2002 89 3 226 297 2-s2.0-0036769089
119. Anderson S. D., Single-dose agents in the prevention of exercise-induced asthma: a descriptive review. Treatments in Respiratory Medicine 2004 3 6 365 379 2-s2.0-12744255262 10.2165/00151829-200403060-00004
120. Parsons J. P., Mastronarde J. G., Exercise-induced bronchoconstriction in athletes. Chest 2005 128 6 3966 3974 2-s2.0-30344466988 10.1378/chest.128.6. 3966 (Pubitemid 43062659)
121. de Benedictis F. M., Vaccher S., de Benedictis D., Montelukast sodium for exercise-induced asthma. Drugs of Today 2008 44 11 845 855 2-s2.0-60949094822 10.1358/dot.2008.44.11.1297498
122. Grzelewski T., Stelmach I., Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options. Drugs 2009 69 12 1533 1553 2-s2.0-68949112246 10.2165/11316720- 000000000-00000
123. Parsons J. P., Mastronarde J. G., Exercise-induced asthma. Current Opinion in Pulmonary Medicine 2009 15 1 25 28 2-s2.0-58149271075 10.1097/MCP.0b013e32831da8ab
124. Duong M., Amin R., Baatjes A. J., Kritzinger F., Qi Y., Meghji Z., Lou W., Grasemann H., O'Byrne P. M., Subbarao P., The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction. Journal of Allergy & Clinical Immunology 2012 130 2 535 539 2-s2.0-84864480397 10.1016/j.jaci.2012.02.051
125. Dahlén B., Treatment of aspirin-intolerant asthma with antileukotrienes. American Journal of Respiratory and Critical Care Medicine 2000 161 2, part 2 S137 S141 2-s2.0-0034058489 (Pubitemid 30129432)
126. Dahlén S.-E., Malmström K., Nizankowska E. W. A., Dahlén B., Kuna P., Kowalski M., Lumry W. R., Picado C., Stevenson D. D., Bousquet J., Pauwels R., Holgate S. T., Shahane A., Zhang J., Reiss T. F., Szczeklik A., Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine 2002 165 1 9 14 2-s2.0-0036142418 (Pubitemid 34053350)
127. Usery J. B., Self T. H., Muthiah M. P., Finch C. K., Potential role of leukotriene modifiers in the treatment of chronic obstructive pulmonary disease. Pharmacotherapy 2008 28 9 1183 1187 2-s2.0-51849112807 10.1592/phco.28.9.1183
128. Celik P., Sakar A., Havlucu Y., Yuksel H., Turkdogan P., Yorgancioglu A., Short-term effects of montelukast in stable patients with moderate to severe COPD. Respiratory Medicine 2005 99 4 444 450 2-s2.0-14844304651 10.1016/j.rmed.2004.09.008 (Pubitemid 40347827)
129. Rubinstein I., Kumar B., Schriever C., Long-term montelukast therapy in moderate to severe COPD-a preliminary observation. Respiratory Medicine 2004 98 2 134 138 2-s2.0-0842323816 10.1016/j.rmed.2003.09.003 (Pubitemid 38181131)
130. Gueli N., Verrusio W., Linguanti A., De Santis W., Canitano N., Ippoliti F., Marigliano V., Cacciafesta M., Montelukast therapy and psychological distress in chronic obstructive pulmonary disease (COPD): a preliminary report. Archives of Gerontology and Geriatrics 2011 52 1 e36 e39 2-s2.0-78649713316 10.1016/j.archger.2010.04.014
131. Zühlke I. E., Kanniess F., Richter K., Nielsen-Gode D., Böhme S., Jörres R. A., Magnussen H., Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD. European Respiratory Journal 2003 22 6 926 930 2-s2.0-0348013231 (Pubitemid 37540643)
132. Cazzola M., Boveri B., Carlucci P., Santus P., DiMarco F., Centanni S., Allegra L., Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT1-receptor antagonist. Pulmonary Pharmacology & Therapeutics 2000 13 6 301 305 2-s2.0-0033675152 10.1006/pupt.2000.0258
133. Nannini L. J. Jr., Flores D. M., Bronchodilator effect of zafirlukast in subjects with chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 2003 16 5 307 311 2-s2.0-0038159930 10.1016/S1094-5539(03) 00072-5 (Pubitemid 36870864)
134. Monteiro A. P., Soledade E., Pinheiro C. S., Pivotal role of 5-lipoxygenase pathway in lung injury after experimental sepsis. American Journal of Respiratory Cell and Molecular Biology 2014 50 1 87 95
135. Kovach M. A., Standiford T. J., The function of neutrophils in sepsis. Current Opinion in Infectious Diseases 2012 25 3 321 327 2-s2.0-84861097666 10.1097/QCO.0b013e3283528c9b
136. de Maeyer N., Kochuyt A.-M., van Moerkercke W., Hiele M., Montelukast as a treatment modality for eosinophilic gastroenteritis. Acta Gastro-Enterologica Belgica 2011 74 4 570 575 2-s2.0-84858036048
137. Riccioni G., di Ilio C., Conti P., Theoharides T. C., D'Orazio N., Advances in therapy with antileukotriene drugs. Annals of Clinical and Laboratory Science 2004 34 4 379 387 2-s2.0-17444425699
138. di Gennaro A., Haeggström J. Z., The leukotrienes: immune-modulating lipid mediators of disease. Advances in Immunology 2012 116 51 92 2-s2.0-84867341631 10.1016/B978-0-12-394300-2.00002-8
139. Simons S. O., Reijers M. H., Montelukast for bronchiolitis Obliterans syndrome after lung transplantation. Chest 2012 141 1 275 276 2-s2.0-84855457844 10.1378/chest.11-1979
140. Al-amran F. G., Hadi N. R., Hashim A. M., Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats. European Journal of Cardio-Thoracic Surgery 2013 43 2 421 427 2-s2.0-84872709079 10.1093/ejcts/ezs312
141. Ochkur S. I., Protheroe C. A., Li W., Cys-leuktrienes promote fibrosis in a mouse model of eosinophil-mediated respiratory inflammation. American Journal of Respiratory Cell and Molecular Biology 2013 49 6 1074 1084
142. Stelmach I., Korzeniewska A., Stelmach W., Majak P., Grzelewski T., Jerzynska J., Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Annals of Allergy, Asthma & Immunology 2005 95 4 372 380 2-s2.0-26944431603 (Pubitemid 41483732)
143. Shimbori C., Shiota N., Okunishi H., Pranlukast, a cysteinyl leukotriene type 1 receptor antagonist, attenuates the progression but not the onset of silica-induced pulmonary fibrosis in mice. International Archives of Allergy and Immunology 2012 158 3 241 251 2-s2.0-84857495469 10.1159/000331439
144. Fireman E., A silica-induced pulmonary fibrosis model: are we closer to 'real life'? International Archives of Allergy and Immunology 2012 158 3 211 212 2-s2.0-84857479013 10.1159/000335237
145. Kato J., Kohyama T., Okazaki H., Desaki M., Nagase T., Rennard S. I., Takizawa H., Leukotriene D4 potentiates fibronectin-induced migration of human lung fibroblasts. Clinical Immunology 2005 117 2 177 181 2-s2.0-26044451796 10.1016/j.clim.2005.07.003 (Pubitemid 41407728)
146. Abe M., Hashimoto S., Hara H., A case of diffuse panbronchiolitis effectively treated with low-dose macrolide antibiotics and leukotriene D4/E4 receptor antagonist. Respiratory Medicine 1998 92 8 1084 1086 2-s2.0-0031670585 10.1016/S0954-6111(98)90361-4 (Pubitemid 28416844)
147. Drakatos P., Lykouras D., Sampsonas F., Karkoulias K., Spiropoulos K., Targeting leukotrienes for the treatment of COPD? Inflammation & Allergy: Drug Targets 2009 8 4 297 306 2-s2.0-70349690768 10.2174/187152809789352177
148. Corless J. A., Warburton C. J., Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2000 4 CD002174 2-s2.0-0034566281
149. Remedios M., Jones D., Kerlin P., Eosinophilic oesophagitis: epidemiology, pathogenesis and management. Drugs 2011 71 5 527 540 2-s2.0-79953211131 10.2165/11585450-000000000-00000
150. Steib C. J., Bilzer M., op den Winkel M., Pfeiler S., Hartmann A. C., Hennenberg M., Göke B., Gerbes A. L., Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology 2010 51 6 2086 2096 2-s2.0-77952732092 10.1002/hep.23596
151. Hattori Y., Ohno T., Ae T., Saeki T., Arai K., Mizuguchi S., Saigenji K., Majima M., Gastric mucosal protection against ethanol by EP2 and EP 4 signaling through the inhibition of leukotriene C4 production. American Journal of Physiology: Gastrointestinal and Liver Physiology 2007 294 1 G80 G87 2-s2.0-38349106719 10.1152/ajpgi.00292.2007
152. Miyaguchi S., Oda M., Saito H., Ishii H., Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy. Hepato-Gastroenterology 1998 45 23 1457 1461 2-s2.0-0031794312 (Pubitemid 28515137)
153. Nishio H., Hayashi Y., Terashima S., Takeuchi K., Protective effect of pranlukast, a cysteinyl-leukotriene receptor 1 antagonist, on indomethacin-induced small intestinal damage in rats. Inflammopharmacology 2007 15 6 266 272 2-s2.0-38849149614 10.1007/s10787-007-1585-1 (Pubitemid 351196135)
154. Capella G. L., Anti-leukotriene drugs in the prevention and treatment of hepatorenal syndrome. Prostaglandins Leukotrienes and Essential Fatty Acids 2003 68 4 263 265 2-s2.0-0037378250 10.1016/S0952-3278(03)00004-8 (Pubitemid 36356761)
155. Tang S.-S., Wang X.-Y., Hong H., Long Y., Li Y.-Q., Xiang G.-Q., Jiang L.-Y., Zhang H.-T., Liu L.-P., Miao M.-X., Hu M., Zhang T.-T., Hu W., Ji H., Ye F.-Y., Leukotriene D4 induces cognitive impairment through enhancement of CysLT1R-mediated amyloid- β generation in mice. Neuropharmacology 2013 65 182 192 2-s2.0-84870924565 10.1016/j.neuropharm.2012.08.026
156. Wang X. Y., Tang S. S., Hu M., Long Y., Li Y. Q., Liao M. X., Ji H., Hong H., Leukotriene D4 induces amyloid- β generation via CysLT 1R-mediated NF- B pathways in primary neurons. Neurochemistry International 2013 62 3 340 347 2-s2.0-84873446333 10.1016/j.neuint.2013.01.002
157. Takahashi Y., Imai K., Ikeda H., Kubota Y., Yamazaki E., Susa F., Open study of pranlukast add-on therapy in intractable partial epilepsy. Brain & Development 2013 35 3 236 244 2-s2.0-84873750737 10.1016/j.braindev.2012.04.001
158. Shi Q.-J., Xiao L., Zhao B., Zhang X.-Y., Wang X.-R., Xu D.-M., Yu S.-Y., Fang S.-H., Lu Y.-B., Zhang W.-P., Sa X.-Y., Wei E.-Q., Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Brain Research 2012 1484 57 67 2-s2.0-84867868654 10.1016/j.brainres. 2012.09.020
159. Fang S. H., Wei E. Q., Zhou Y., Wang M. L., Zhang W. P., Yu G. L., Chu L. S., Chen Z., Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience 2006 140 3 969 979 2-s2.0-33646795009 10.1016/j. neuroscience.2006.02.051 (Pubitemid 43767454)
160. Qian X.-D., Wei E.-Q., Zhang L., Sheng W.-W., Wang M.-L., Zhang W.-P., Chen Z., Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, protects mice against brain cold injury. European Journal of Pharmacology 2006 549 1-3 35 40 2-s2.0-33748961961 10.1016/j.ejphar.2006.07.056 (Pubitemid 44441263)
161. Wang L., Du C., Lv J., Wei W., Cui Y., Xie X., Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis. The Journal of Immunology 2011 187 5 2336 2345 2-s2.0-80052672267 10.4049/jimmunol.1100333
162. Holme H., Winckworth L. C., Montelukast can reduce the severity and extent of atopic dermatitis. Journal of Paediatrics and Child Health 2013 49 5 412 415 2-s2.0-84877301965 10.1111/jpc.12202
163. Kosnik M., Subic T., Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria. Respiratory Medicine 2011 105 1 S84 S88 2-s2.0-80054999123 10.1016/S0954-6111(11)70018-X
164. Zemtsov A., Ali-Moncada S., Leukotriene inhibitor may be effective in treatment of psoriasis. Acta Dermato-Venereologica 2000 80 5 389 2-s2.0-0034544832 (Pubitemid 32014465)
165. Zemtsov A., Bucchino S., McDowell M. R., Potential use of leukotriene inhibitors in treatment of psoriasis. Dermatology 2003 206 2 179 180 2-s2.0-0037275233 10.1159/000068468 (Pubitemid 36205292)
166. Nobili E., Salvado M. D., Folkersen L., Castiglioni L., Kastrup J., Wetterholm A., Tremoli E., Hansson G. K., Sironi L., Haeggström J. Z., Gabrielsen A., Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease. PLoS ONE 2012 7 7 2-s2.0-84864363914 10.1371/journal.pone.0041786 e41786
167. Turner P. J., Kemp A. S., Rogers M., Mehr S., Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatric Dermatology 2012 29 2 222 223 2-s2.0-84859109120 10.1111/j.1525-1470.2011.01576.x
168. Yoshikawa D., Goto F., Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: role of the leukocyte. Circulatory Shock 1992 38 1 29 33 2-s2.0-0026784185
169. Huerva V., Oral leukotriene antagonists in thyroid eye disease: myth or reality? Ophthalmic Plastic & Reconstructive Surgery 2011 27 5 398 2-s2.0-80052746935 10.1097/IOP.0b013e31820828f5
170. Kuhle S., Urschitz M. S., Anti-inflammatory medications for obstructive sleep apnea in children. Cochrane Database of Systematic Reviews 2011 1 CD007074 2-s2.0-79952258191
171. Nozaki M., Yoshikawa M., Ishitani K., Kobayashi H., Houkin K., Imai K., Ito Y., Muraki T., Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability. The Keio Journal of Medicine 2010 59 1 10 18 2-s2.0-77954258075 10.2302/kjm.59.10
172. Tada N., Furukawa M., Ogura M., Arai S., Adachi Y., Ikehara S., Yamashita T., Experimental otitis media with effusion induced by leukotriene D4. Auris Nasus Larynx 2002 29 2 127 132 2-s2.0-0036129460 10.1016/S0385-8146(01)00143-2 (Pubitemid 34230362)
173. Sapountzis S., Kim J. H., Francescato Veiga D., Masako Ferreira L., The effect of zafirlukast on capsule formation in post-radiation silicone implants. Medical Hypotheses 2012 78 6 787 789 2-s2.0-84860368034 10.1016/j.mehy.2012.03. 007
174. Goldmeier D., Madden P., McKenna M., Tamm N., Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study. International Journal of STD & AIDS 2005 16 3 196 200 2-s2.0-16344382736 10.1258/0956462053420239 (Pubitemid 40469853)
175. White D. J., Vanthuyne A., Wood P. M., Ayres J. G., Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study. Sexually Transmitted Infections 2004 80 3 219 222 2-s2.0-2942548858 10.1136/sti.2002. 003491 (Pubitemid 38746200)